Advertisement

 

 

Validation of a questionnaire to monitor symptoms in HIV-infected patients during hepatitis C treatment.

Validation of a questionnaire to monitor symptoms in HIV-infected patients during hepatitis C treatment.
Author Information (click to view)

Cachay ER, Ballard C, Colwell B, Torriani F, Hicks C, Mathews WC,


Cachay ER, Ballard C, Colwell B, Torriani F, Hicks C, Mathews WC, (click to view)

Cachay ER, Ballard C, Colwell B, Torriani F, Hicks C, Mathews WC,

Advertisement

AIDS research and therapy 2017 09 2014(1) 56 doi 10.1186/s12981-017-0182-7

Abstract
BACKGROUND
Clinicians are incorporating patient-reported outcomes in the management of HIV-infected persons co-infected with hepatitis C virus (HCV), but there are no validated inventories to monitor symptoms of patients during HCV therapy.

DESIGN
Five-year retrospective cohort analysis of persons living with HIV (PLWH) treated for HCV.

METHODS
The HCV symptom-inventory (HCV-SI) was administered before, during, and after HCV treatment. Discriminant validity was assessed, separately, in mixed model linear regression of HCV-SI T-scores on treatment regimens (pegylated-interferon and ribavirin; pegylated-interferon, ribavirin, and telaprevir; and interferon-free antivirals); and side effect-related premature treatment discontinuation (SE-DC).

RESULTS
From the 103 patients who completed the HCV-SI, 7% were female, 26% non-white, 32% cirrhotics and 91% had undetectable HIV viral loads. Most had genotype 1 (83%) and were HCV treatment-naïve (78%). We treated 19% of patients with pegylated-interferon and ribavirin, 22% with pegylated-interferon, ribavirin, and telaprevir and 59% received interferon-free antivirals. Overall, 77% achieved a sustained virologic response, and 6% discontinued HCV treatment due to side effects. In the treatment discrimination model, compared to the no treatment period, HCV-SI scores were significantly (p < 0.01) lower for interferon-free antivirals and higher for interferon-containing regimens. In the SE-DC model, the total HCV-SI, somatic and neuropsychiatric scores significantly predicted those patients who prematurely discontinued HCV treatment (P < 0.05). CONCLUSIONS
The HCV-SI effectively differentiated among treatment regimens known to vary by side effect profiles and between patients with and without treatment discontinuation due to side effects. The HCV-SI may have value as a patient-reported outcome instrument predicting the risk of HCV treatment discontinuation.

Submit a Comment

Your email address will not be published. Required fields are marked *

sixteen + 17 =

[ HIDE/SHOW ]